Influenza virus infections in patients with malignancies -- characteristics and outcome of the season 2014/15. A survey conducted by the Infectious Diseases Working Party (AGIHO) of the German Society of Haematology and Medical Oncology (DGHO).
Identifieur interne : 000068 ( Main/Corpus ); précédent : 000067; suivant : 000069Influenza virus infections in patients with malignancies -- characteristics and outcome of the season 2014/15. A survey conducted by the Infectious Diseases Working Party (AGIHO) of the German Society of Haematology and Medical Oncology (DGHO).
Auteurs : B. Hermann ; N. Lehners ; M. Brodhun ; K. Boden ; A. Hochhaus ; M. Kochanek ; K. Meckel ; K. Mayer ; T. Rachow ; C. Rieger ; E. Schalk ; T. Weber ; A. Schmeier-Jürchott ; P. Schlattmann ; D. Teschner ; M. Von Lilienfeld-ToalSource :
- European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology [ 1435-4373 ] ; 2017.
English descriptors
- KwdEn :
- Aged, Antiviral Agents (therapeutic use), Critical Care, Female, Germany (epidemiology), Humans, Influenza A virus (isolation & purification), Influenza B virus (isolation & purification), Influenza, Human (epidemiology), Influenza, Human (mortality), Influenza, Human (pathology), Influenza, Human (virology), Male, Middle Aged, Neoplasms (complications), Oseltamivir (therapeutic use), Risk Factors, Societies, Superinfection (epidemiology), Survival Analysis, Treatment Outcome.
- MESH :
- chemical , therapeutic use : Antiviral Agents, Oseltamivir.
- complications : Neoplasms.
- epidemiology : Germany, Influenza, Human, Superinfection.
- isolation & purification : Influenza A virus, Influenza B virus.
- mortality : Influenza, Human.
- pathology : Influenza, Human.
- virology : Influenza, Human.
- Aged, Critical Care, Female, Humans, Male, Middle Aged, Risk Factors, Societies, Survival Analysis, Treatment Outcome.
Abstract
Influenza virus infections (IVI) may pose a vital threat to immunocompromised patients such as those suffering from malignancies, but specific data on epidemiology and outcome in these patients are scarce. In this study, we collected data on patients with active cancer or with a history of cancer, presenting with documented IVI in eight centres in Germany. Two hundred and three patients were identified, suffering from haematological malignancies or solid tumours; 109 (54 %) patients had active malignant disease. Influenza A was detected in 155 (77 %) and Influenza B in 46 (23 %) of patients (genera not determined in two patients). Clinical symptoms were consistent with upper respiratory tract infection in 55/203 (27 %), influenza-like illness in 82/203 (40 %), and pneumonia in 67/203 (33 %). Anti-viral treatment with oseltamivir was received by 116/195 (59 %). Superinfections occurred in 37/203 (18 %), and admission on an intensive care unit was required in 26/203 (13 %). Seventeen patients (9 %) died. Independent risk factors for death were delayed diagnosis of IVI and bacterial or fungal superinfection, but not underlying malignancy or ongoing immunosuppression. In conclusion, patients with IVI show high rates of pneumonia and mortality. Early and rapid diagnosis is essential. The high rate of pneumonia and superinfections should be taken into account when managing IVI in these patients.
DOI: 10.1007/s10096-016-2833-3
PubMed: 27838792
Links to Exploration step
pubmed:27838792Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Influenza virus infections in patients with malignancies -- characteristics and outcome of the season 2014/15. A survey conducted by the Infectious Diseases Working Party (AGIHO) of the German Society of Haematology and Medical Oncology (DGHO).</title><author><name sortKey="Hermann, B" sort="Hermann, B" uniqKey="Hermann B" first="B" last="Hermann">B. Hermann</name><affiliation><nlm:affiliation>Leibniz Institut für Naturstoff-Forschung und Infektionsbiologie, Hans-Knöll-Institut, 07745 , Jena, Germany. eckidtdf@mailbox.alumni.tu-berlin.de.</nlm:affiliation></affiliation></author><author><name sortKey="Lehners, N" sort="Lehners, N" uniqKey="Lehners N" first="N" last="Lehners">N. Lehners</name><affiliation><nlm:affiliation>Department of Haematology and Oncology, University Hospital Heidelberg, Heidelberg, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Brodhun, M" sort="Brodhun, M" uniqKey="Brodhun M" first="M" last="Brodhun">M. Brodhun</name><affiliation><nlm:affiliation>Medizinische Klinik II, Abteilung für Haematologie und internistische Onkologie, Universitätsklinikum Jena, Jena, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Boden, K" sort="Boden, K" uniqKey="Boden K" first="K" last="Boden">K. Boden</name><affiliation><nlm:affiliation>Institut für Klinische Chemie und Laboratoriumsmedizin, University Hospital Jena, Jena, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Hochhaus, A" sort="Hochhaus, A" uniqKey="Hochhaus A" first="A" last="Hochhaus">A. Hochhaus</name><affiliation><nlm:affiliation>Medizinische Klinik II, Abteilung für Haematologie und internistische Onkologie, Universitätsklinikum Jena, Jena, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Kochanek, M" sort="Kochanek, M" uniqKey="Kochanek M" first="M" last="Kochanek">M. Kochanek</name><affiliation><nlm:affiliation>Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Meckel, K" sort="Meckel, K" uniqKey="Meckel K" first="K" last="Meckel">K. Meckel</name><affiliation><nlm:affiliation>Medizinische Klinik II, Abteilung für Haematologie und internistische Onkologie, Universitätsklinikum Jena, Jena, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Mayer, K" sort="Mayer, K" uniqKey="Mayer K" first="K" last="Mayer">K. Mayer</name><affiliation><nlm:affiliation>Medizinische Klinik III, University Hospital Bonn, Bonn, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Rachow, T" sort="Rachow, T" uniqKey="Rachow T" first="T" last="Rachow">T. Rachow</name><affiliation><nlm:affiliation>Medizinische Klinik II, Abteilung für Haematologie und internistische Onkologie, Universitätsklinikum Jena, Jena, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Rieger, C" sort="Rieger, C" uniqKey="Rieger C" first="C" last="Rieger">C. Rieger</name><affiliation><nlm:affiliation>Internistische Lehrpraxis der Ludwig-Maximilians-Universität München, University of Munich, Munich, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Schalk, E" sort="Schalk, E" uniqKey="Schalk E" first="E" last="Schalk">E. Schalk</name><affiliation><nlm:affiliation>Otto-von-Guericke University Magdeburg, Medical Centre, Department of Haematology and Oncology, Magdeburg, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Weber, T" sort="Weber, T" uniqKey="Weber T" first="T" last="Weber">T. Weber</name><affiliation><nlm:affiliation>University Hospital Halle, Halle, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Schmeier Jurchott, A" sort="Schmeier Jurchott, A" uniqKey="Schmeier Jurchott A" first="A" last="Schmeier-Jürchott">A. Schmeier-Jürchott</name><affiliation><nlm:affiliation>University Medical Centre of the Johannes Gutenberg University, Mainz, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Schlattmann, P" sort="Schlattmann, P" uniqKey="Schlattmann P" first="P" last="Schlattmann">P. Schlattmann</name><affiliation><nlm:affiliation>Department of Medical Statistics, Informatics and Documentation, University Hospital Jena, Jena, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Teschner, D" sort="Teschner, D" uniqKey="Teschner D" first="D" last="Teschner">D. Teschner</name><affiliation><nlm:affiliation>University Medical Centre of the Johannes Gutenberg University, Mainz, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Von Lilienfeld Toal, M" sort="Von Lilienfeld Toal, M" uniqKey="Von Lilienfeld Toal M" first="M" last="Von Lilienfeld-Toal">M. Von Lilienfeld-Toal</name><affiliation><nlm:affiliation>Leibniz Institut für Naturstoff-Forschung und Infektionsbiologie, Hans-Knöll-Institut, 07745 , Jena, Germany.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Medizinische Klinik II, Abteilung für Haematologie und internistische Onkologie, Universitätsklinikum Jena, Jena, Germany.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Forschungscampus InfectoGnostics, Jena, Germany.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Integriertes Forschungs- und Behandlungszentrum Sepsis und Sepsisfolgen (CSCC), Universitätsklinikum Jena, Jena, Germany.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:27838792</idno><idno type="pmid">27838792</idno><idno type="doi">10.1007/s10096-016-2833-3</idno><idno type="wicri:Area/Main/Corpus">000068</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000068</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Influenza virus infections in patients with malignancies -- characteristics and outcome of the season 2014/15. A survey conducted by the Infectious Diseases Working Party (AGIHO) of the German Society of Haematology and Medical Oncology (DGHO).</title><author><name sortKey="Hermann, B" sort="Hermann, B" uniqKey="Hermann B" first="B" last="Hermann">B. Hermann</name><affiliation><nlm:affiliation>Leibniz Institut für Naturstoff-Forschung und Infektionsbiologie, Hans-Knöll-Institut, 07745 , Jena, Germany. eckidtdf@mailbox.alumni.tu-berlin.de.</nlm:affiliation></affiliation></author><author><name sortKey="Lehners, N" sort="Lehners, N" uniqKey="Lehners N" first="N" last="Lehners">N. Lehners</name><affiliation><nlm:affiliation>Department of Haematology and Oncology, University Hospital Heidelberg, Heidelberg, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Brodhun, M" sort="Brodhun, M" uniqKey="Brodhun M" first="M" last="Brodhun">M. Brodhun</name><affiliation><nlm:affiliation>Medizinische Klinik II, Abteilung für Haematologie und internistische Onkologie, Universitätsklinikum Jena, Jena, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Boden, K" sort="Boden, K" uniqKey="Boden K" first="K" last="Boden">K. Boden</name><affiliation><nlm:affiliation>Institut für Klinische Chemie und Laboratoriumsmedizin, University Hospital Jena, Jena, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Hochhaus, A" sort="Hochhaus, A" uniqKey="Hochhaus A" first="A" last="Hochhaus">A. Hochhaus</name><affiliation><nlm:affiliation>Medizinische Klinik II, Abteilung für Haematologie und internistische Onkologie, Universitätsklinikum Jena, Jena, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Kochanek, M" sort="Kochanek, M" uniqKey="Kochanek M" first="M" last="Kochanek">M. Kochanek</name><affiliation><nlm:affiliation>Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Meckel, K" sort="Meckel, K" uniqKey="Meckel K" first="K" last="Meckel">K. Meckel</name><affiliation><nlm:affiliation>Medizinische Klinik II, Abteilung für Haematologie und internistische Onkologie, Universitätsklinikum Jena, Jena, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Mayer, K" sort="Mayer, K" uniqKey="Mayer K" first="K" last="Mayer">K. Mayer</name><affiliation><nlm:affiliation>Medizinische Klinik III, University Hospital Bonn, Bonn, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Rachow, T" sort="Rachow, T" uniqKey="Rachow T" first="T" last="Rachow">T. Rachow</name><affiliation><nlm:affiliation>Medizinische Klinik II, Abteilung für Haematologie und internistische Onkologie, Universitätsklinikum Jena, Jena, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Rieger, C" sort="Rieger, C" uniqKey="Rieger C" first="C" last="Rieger">C. Rieger</name><affiliation><nlm:affiliation>Internistische Lehrpraxis der Ludwig-Maximilians-Universität München, University of Munich, Munich, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Schalk, E" sort="Schalk, E" uniqKey="Schalk E" first="E" last="Schalk">E. Schalk</name><affiliation><nlm:affiliation>Otto-von-Guericke University Magdeburg, Medical Centre, Department of Haematology and Oncology, Magdeburg, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Weber, T" sort="Weber, T" uniqKey="Weber T" first="T" last="Weber">T. Weber</name><affiliation><nlm:affiliation>University Hospital Halle, Halle, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Schmeier Jurchott, A" sort="Schmeier Jurchott, A" uniqKey="Schmeier Jurchott A" first="A" last="Schmeier-Jürchott">A. Schmeier-Jürchott</name><affiliation><nlm:affiliation>University Medical Centre of the Johannes Gutenberg University, Mainz, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Schlattmann, P" sort="Schlattmann, P" uniqKey="Schlattmann P" first="P" last="Schlattmann">P. Schlattmann</name><affiliation><nlm:affiliation>Department of Medical Statistics, Informatics and Documentation, University Hospital Jena, Jena, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Teschner, D" sort="Teschner, D" uniqKey="Teschner D" first="D" last="Teschner">D. Teschner</name><affiliation><nlm:affiliation>University Medical Centre of the Johannes Gutenberg University, Mainz, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Von Lilienfeld Toal, M" sort="Von Lilienfeld Toal, M" uniqKey="Von Lilienfeld Toal M" first="M" last="Von Lilienfeld-Toal">M. Von Lilienfeld-Toal</name><affiliation><nlm:affiliation>Leibniz Institut für Naturstoff-Forschung und Infektionsbiologie, Hans-Knöll-Institut, 07745 , Jena, Germany.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Medizinische Klinik II, Abteilung für Haematologie und internistische Onkologie, Universitätsklinikum Jena, Jena, Germany.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Forschungscampus InfectoGnostics, Jena, Germany.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Integriertes Forschungs- und Behandlungszentrum Sepsis und Sepsisfolgen (CSCC), Universitätsklinikum Jena, Jena, Germany.</nlm:affiliation></affiliation></author></analytic><series><title level="j">European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology</title><idno type="eISSN">1435-4373</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Antiviral Agents (therapeutic use)</term><term>Critical Care</term><term>Female</term><term>Germany (epidemiology)</term><term>Humans</term><term>Influenza A virus (isolation & purification)</term><term>Influenza B virus (isolation & purification)</term><term>Influenza, Human (epidemiology)</term><term>Influenza, Human (mortality)</term><term>Influenza, Human (pathology)</term><term>Influenza, Human (virology)</term><term>Male</term><term>Middle Aged</term><term>Neoplasms (complications)</term><term>Oseltamivir (therapeutic use)</term><term>Risk Factors</term><term>Societies</term><term>Superinfection (epidemiology)</term><term>Survival Analysis</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term><term>Oseltamivir</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Neoplasms</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Germany</term><term>Influenza, Human</term><term>Superinfection</term></keywords><keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>Influenza A virus</term><term>Influenza B virus</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Critical Care</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Risk Factors</term><term>Societies</term><term>Survival Analysis</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Influenza virus infections (IVI) may pose a vital threat to immunocompromised patients such as those suffering from malignancies, but specific data on epidemiology and outcome in these patients are scarce. In this study, we collected data on patients with active cancer or with a history of cancer, presenting with documented IVI in eight centres in Germany. Two hundred and three patients were identified, suffering from haematological malignancies or solid tumours; 109 (54 %) patients had active malignant disease. Influenza A was detected in 155 (77 %) and Influenza B in 46 (23 %) of patients (genera not determined in two patients). Clinical symptoms were consistent with upper respiratory tract infection in 55/203 (27 %), influenza-like illness in 82/203 (40 %), and pneumonia in 67/203 (33 %). Anti-viral treatment with oseltamivir was received by 116/195 (59 %). Superinfections occurred in 37/203 (18 %), and admission on an intensive care unit was required in 26/203 (13 %). Seventeen patients (9 %) died. Independent risk factors for death were delayed diagnosis of IVI and bacterial or fungal superinfection, but not underlying malignancy or ongoing immunosuppression. In conclusion, patients with IVI show high rates of pneumonia and mortality. Early and rapid diagnosis is essential. The high rate of pneumonia and superinfections should be taken into account when managing IVI in these patients.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27838792</PMID><DateCompleted><Year>2017</Year><Month>02</Month><Day>22</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1435-4373</ISSN><JournalIssue CitedMedium="Internet"><Volume>36</Volume><Issue>3</Issue><PubDate><Year>2017</Year><Month>Mar</Month></PubDate></JournalIssue><Title>European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology</Title><ISOAbbreviation>Eur. J. Clin. Microbiol. Infect. Dis.</ISOAbbreviation></Journal><ArticleTitle>Influenza virus infections in patients with malignancies -- characteristics and outcome of the season 2014/15. A survey conducted by the Infectious Diseases Working Party (AGIHO) of the German Society of Haematology and Medical Oncology (DGHO).</ArticleTitle><Pagination><MedlinePgn>565-573</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10096-016-2833-3</ELocationID><Abstract><AbstractText>Influenza virus infections (IVI) may pose a vital threat to immunocompromised patients such as those suffering from malignancies, but specific data on epidemiology and outcome in these patients are scarce. In this study, we collected data on patients with active cancer or with a history of cancer, presenting with documented IVI in eight centres in Germany. Two hundred and three patients were identified, suffering from haematological malignancies or solid tumours; 109 (54 %) patients had active malignant disease. Influenza A was detected in 155 (77 %) and Influenza B in 46 (23 %) of patients (genera not determined in two patients). Clinical symptoms were consistent with upper respiratory tract infection in 55/203 (27 %), influenza-like illness in 82/203 (40 %), and pneumonia in 67/203 (33 %). Anti-viral treatment with oseltamivir was received by 116/195 (59 %). Superinfections occurred in 37/203 (18 %), and admission on an intensive care unit was required in 26/203 (13 %). Seventeen patients (9 %) died. Independent risk factors for death were delayed diagnosis of IVI and bacterial or fungal superinfection, but not underlying malignancy or ongoing immunosuppression. In conclusion, patients with IVI show high rates of pneumonia and mortality. Early and rapid diagnosis is essential. The high rate of pneumonia and superinfections should be taken into account when managing IVI in these patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hermann</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Leibniz Institut für Naturstoff-Forschung und Infektionsbiologie, Hans-Knöll-Institut, 07745 , Jena, Germany. eckidtdf@mailbox.alumni.tu-berlin.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lehners</LastName><ForeName>N</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Haematology and Oncology, University Hospital Heidelberg, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brodhun</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Medizinische Klinik II, Abteilung für Haematologie und internistische Onkologie, Universitätsklinikum Jena, Jena, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boden</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Institut für Klinische Chemie und Laboratoriumsmedizin, University Hospital Jena, Jena, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hochhaus</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Medizinische Klinik II, Abteilung für Haematologie und internistische Onkologie, Universitätsklinikum Jena, Jena, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kochanek</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meckel</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Medizinische Klinik II, Abteilung für Haematologie und internistische Onkologie, Universitätsklinikum Jena, Jena, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mayer</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Medizinische Klinik III, University Hospital Bonn, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rachow</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Medizinische Klinik II, Abteilung für Haematologie und internistische Onkologie, Universitätsklinikum Jena, Jena, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rieger</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Internistische Lehrpraxis der Ludwig-Maximilians-Universität München, University of Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schalk</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Otto-von-Guericke University Magdeburg, Medical Centre, Department of Haematology and Oncology, Magdeburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weber</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>University Hospital Halle, Halle, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmeier-Jürchott</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>University Medical Centre of the Johannes Gutenberg University, Mainz, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schlattmann</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Medical Statistics, Informatics and Documentation, University Hospital Jena, Jena, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teschner</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>University Medical Centre of the Johannes Gutenberg University, Mainz, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>von Lilienfeld-Toal</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Leibniz Institut für Naturstoff-Forschung und Infektionsbiologie, Hans-Knöll-Institut, 07745 , Jena, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medizinische Klinik II, Abteilung für Haematologie und internistische Onkologie, Universitätsklinikum Jena, Jena, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Forschungscampus InfectoGnostics, Jena, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Integriertes Forschungs- und Behandlungszentrum Sepsis und Sepsisfolgen (CSCC), Universitätsklinikum Jena, Jena, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>11</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Eur J Clin Microbiol Infect Dis</MedlineTA><NlmUniqueID>8804297</NlmUniqueID><ISSNLinking>0934-9723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>20O93L6F9H</RegistryNumber><NameOfSubstance UI="D053139">Oseltamivir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Eur Rev Med Pharmacol Sci. 2020 Apr;24(7):3434-3436</RefSource><PMID Version="1">32329810</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003422" MajorTopicYN="N">Critical Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N">Germany</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009980" MajorTopicYN="N">Influenza A virus</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009981" MajorTopicYN="N">Influenza B virus</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053139" MajorTopicYN="N">Oseltamivir</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012952" MajorTopicYN="N">Societies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015163" MajorTopicYN="N">Superinfection</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Compliance with ethical standardsFundingPartially funded by Infectognostics Forschungscampus, grant number BMBF 13GW0096D.Conflicts of interestMarie von Lilienfeld-Toal: honoraria, travel grant, and research grant from MSD and Celgene. Honoraria and travel grant from Gilead, Janssen Cilag, and Astellas. Consultant of advisory board for MSD.Daniel Teschner: honoraria and travel grant from Gilead and MSD. Travel grant from Astellas and Jazz. Consultant of advisory board for MSD and Pfizer.Andreas Hochhaus: research support from Novartis, BMS, Pfizer, AriadBeate Hermann: noneNicola Lehners: noneMaria Brodhun, Katharina Boden, Matthias Kochanek, Katharina Meckel, Karin Mayer, Tobias Rachow, Christina Rieger, Enrico Schalk, Thomas Weber, Anna Schmeier-Jürchott, Peter Schlattmann: noneEthical approvalThe study was approved by the ethics committee of Jena University Hospital (3785-05/13).Informed consentNo informed consent was required since this was a retrospective study.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>10</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>10</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>11</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>11</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27838792</ArticleId><ArticleId IdType="doi">10.1007/s10096-016-2833-3</ArticleId><ArticleId IdType="pii">10.1007/s10096-016-2833-3</ArticleId><ArticleId IdType="pmc">PMC5309266</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Respir Med. 2010 Jul;104(7):1050-6</Citation><ArticleIdList><ArticleId IdType="pubmed">20181467</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer. 2012 Sep 15;118(18):4627-33</Citation><ArticleIdList><ArticleId IdType="pubmed">22359314</ArticleId></ArticleIdList></Reference><Reference><Citation>Transpl Infect Dis. 2013 Jun;15(3):219-32</Citation><ArticleIdList><ArticleId IdType="pubmed">23363310</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2004 Nov 1;39(9):1300-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15494906</ArticleId></ArticleIdList></Reference><Reference><Citation>Antivir Ther. 2016;21(5):413-24</Citation><ArticleIdList><ArticleId IdType="pubmed">26867096</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2010 Aug 1;51 Suppl 1:S81-7</Citation><ArticleIdList><ArticleId IdType="pubmed">20597676</ArticleId></ArticleIdList></Reference><Reference><Citation>Transpl Infect Dis. 2009 Apr;11(2):100-5</Citation><ArticleIdList><ArticleId IdType="pubmed">19175540</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Hematol. 2011 Jan;90(1):117-8</Citation><ArticleIdList><ArticleId IdType="pubmed">20432037</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Microbiol Immunol. 2002 Dec;191(3-4):165-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12458353</ArticleId></ArticleIdList></Reference><Reference><Citation>Haematologica. 2011 Aug;96(8):1231-5</Citation><ArticleIdList><ArticleId IdType="pubmed">21546495</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Invest. 1959 Jan;38(1 Part 2):213-65</Citation><ArticleIdList><ArticleId IdType="pubmed">13620784</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Hematol. 2014 Apr;93(4):669-76</Citation><ArticleIdList><ArticleId IdType="pubmed">24097084</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Pulm Med. 2013 May;19(3):244-50</Citation><ArticleIdList><ArticleId IdType="pubmed">23508112</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2011 May 12;117(19):5050-6</Citation><ArticleIdList><ArticleId IdType="pubmed">21372154</ArticleId></ArticleIdList></Reference><Reference><Citation>Chest. 2005 Jan;127(1):213-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15653986</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2010 Feb 18;115(7):1331-42</Citation><ArticleIdList><ArticleId IdType="pubmed">20009037</ArticleId></ArticleIdList></Reference><Reference><Citation>Medicine (Baltimore). 2006 Sep;85(5):278-87</Citation><ArticleIdList><ArticleId IdType="pubmed">16974212</ArticleId></ArticleIdList></Reference><Reference><Citation>Bone Marrow Transplant. 2004 Jul;34(2):111-4</Citation><ArticleIdList><ArticleId IdType="pubmed">15094755</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Pathol. 2010 Feb;176(2):536-9</Citation><ArticleIdList><ArticleId IdType="pubmed">20019194</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Blood Marrow Transplant. 2005 Oct;11(10):781-96</Citation><ArticleIdList><ArticleId IdType="pubmed">16182179</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Oncol. 2015 Jan;26(1):21-33</Citation><ArticleIdList><ArticleId IdType="pubmed">24833776</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2008 Oct 1;198(7):962-70</Citation><ArticleIdList><ArticleId IdType="pubmed">18710327</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Exp Immunol. 2004 Jul;137(1):8-11</Citation><ArticleIdList><ArticleId IdType="pubmed">15196237</ArticleId></ArticleIdList></Reference><Reference><Citation>Diagn Microbiol Infect Dis. 2003 Apr;45(4):279-85</Citation><ArticleIdList><ArticleId IdType="pubmed">12730000</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/GrippeAllemagneV3/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000068 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000068 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= GrippeAllemagneV3
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:27838792
|texte= Influenza virus infections in patients with malignancies -- characteristics and outcome of the season 2014/15. A survey conducted by the Infectious Diseases Working Party (AGIHO) of the German Society of Haematology and Medical Oncology (DGHO).
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:27838792" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a GrippeAllemagneV3
| This area was generated with Dilib version V0.6.35. |  |